Progyny Inc

Progyny maintains a strong liquidity position with $112.2 million in cash and equivalents, representing 15.1% of total assets, and a current ratio of 2.73, well above the industry median of 1.4. The company has no long-term debt and a debt-to-equity ratio of 0.0, indicating a conservative capital structure. Profitability metrics show a return on equity (ROE) of 11.34% and return on assets (ROA) of 7.88%, both exceeding the industry median of 6.2% and 4.1%, respectively. Net income of $58.5 million on $1.3 billion in revenue reflects a net margin of 4.5%, slightly above the industry median of 4.0%. Geographically, Progyny's revenue is concentrated in the United States, with no material international exposure disclosed. The company operates in a single business segment focused on fertility services, with no material diversification across product lines or geographic regions. Revenue growth has been modest, with a year-over-year increase of 2.1% in FY2024. Outlook for FY2025 suggests a 3.5% revenue growth, driven by expanded insurance partnerships and new market entry in three states. Risk factors include regulatory uncertainty in fertility coverage and potential dilution from a $50 million ATM facility. No immediate dilution pressure is observed, with shares outstanding unchanged at 78.3 million for both basic and diluted shares. Recent events include a Q2 2024 earnings call highlighting improved patient acquisition and a 10-K filing disclosing no material litigation. Analysts have assigned a mean price target of $27.55, with 9 "buy" and 4 "strong buy" ratings.